PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7635005

Moclobemide for depression.

View original source ↗Export metadata ↓

Abstract

Moclobemide (Manerix--Roche), the first of a new class of antidepressant drugs, was launched in the UK last year. It is a reversible inhibitor of monoamine oxidase A, which the manufacturer claims is a "first line treatment for major depression". Is this claim justified?

Explore related subjects

Antidepressive AgentsBenzamidesDepressive DisorderHumansMoclobemideMonoamine Oxidase InhibitorsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

1994-01-20. Moclobemide for depression.. https://pubmed.ncbi.nlm.nih.gov/7635005/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Panic disorder.

Panic disorder is a chronic illness that affects at least 3 percent of the population. Panic disorder is associated with significant morbidity and an increased risk of suicide. Patients generally present with multiple somatic and psychologic complaints, including heart palpitations, chest pain, tremor, shortness of breath, choking, nausea or abdominal distress, dizziness, derealization, fear of losing control or going crazy, fear of dying, paresthesias, chills or hot flushes, headache, diarrhea, insomnia, chronic fatigue, anxiety and depression. To make the correct diagnosis, these symptoms must be evaluated carefully since they also occur with serious cardiovascular, pulmonary, endocrinologic and neurologic disorders. Many effective treatments are available, including tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, benzodiazepines such as alprazolam and clonazepam, and psychotherapy.

Antidepressive Agents↗